Dengue, Chikungunya, and Zika illnesses have rapidly expanded across the globe in recent years, causing large-scale outbreaks worldwide. Through affordable and early detection, our mission at E25Bio is to prevent severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread.
With a highly-specific and sensitive rapid test along with phone-enabled data analytics of diagnosis, we present the first all-in-one solution for real-time simultaneous diagnostics of dengue, Zika and Chikungunya.
At E25Bio, we develop a low-cost and accurate solution to more effectively facilitate epidemiologic predictions and disease mapping in order to reach, diagnose and treat the greatest number of patients. With only a finger prick, our multiplexed test can swiftly detect the proteins produced by viral infection of dengue, Chikungunya or Zika – all in one device.
With 3.8 billion people in endemic areas and 128 countries affected by mosquito-borne viruses, rapid and early diagnostics are crucial for the management of epidemics and cases worldwide. Our easy-to-use technology is a low-cost rapid device that provides fast and accurate point-of-care results with no cross reactivity. Such a device transforms patient health outcomes by providing correct disease diagnosis, resulting in proper treatment protocols.
We are building the future of rapid diagnostics worldwide.
Today’s advancements in biological sciences and technology are transforming traditional approaches to healthcare -- uprooting entrenched methodologies and practices and clearing the path for new strategies and actions. Conventional medicine practice, patient treatment protocols, and disease control strategies are changing in the advent of swifter, more agile and accessible techniques. The future is here.